In the context of endometrial cancer (EC) patients classified as high-intermediate-risk and high-risk, it is pertinent to discuss the influence of varying co-expression patterns of CD44 & CD133—low, mixed, and high—on the efficacy of adjuvant therapy. The gene discussed is CD44; the disease is endometrial cancer.